Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated

Company type	Public
Traded as	Nasdaq: VRTX Nasdaq-100 component S&P 500 component
Industry	Pharmaceuticals Biotherapeutics
Founded	1989; 35 years ago (1989)
Headquarters	Boston, Massachusetts, U.S.
Key people	Reshma Kewalramani (president and CEO) Jeffrey Leiden (chairman) David Altshuler (CSO)
Products	Pharmaceuticals
Revenue	US$9.87 billion (2023)
Operating income	US$3.83 billion (2023)
Net income	US$3.62 billion (2023)
Total assets	US$22.7 billion (2023)
Total equity	US$17.6 billion (2023)
Number of employees	c. 5,400 (2023)
Website	vrtx.com
Footnotes / references [1][2]

Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in South Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.